FindTrial
Sign In

The Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management of Cardiogenic Shock Complicated by Acute Myocardial Infarction: A prospective randomized controlled trial

The Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management of Cardiogenic Shock Complicated by Acute Myocardial Infarction: A prospective randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114346
Enrollment
Unknown
Registered
2025-12-10
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic Shock Complicated by Acute Myocardial Infarction

Interventions

levosimendan group:levosimendan
Control group:Saline

Sponsors

The People’s Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include adult patients (aged =18 years) who are diagnosed as cardiogenic shock following acute myocardial infarction and scheduled to undergo venoarterial extracorporeal membrane oxygenation (VA-ECMO) with or without levosimendan.

Exclusion criteria

Exclusion criteria: Patients with stroke, previous percutaneous coronary intervention or coronary artery bypass grafting and those who died within 24 hours after being admitted to hospital are excluded from the study.

Design outcomes

Primary

MeasureTime frame
In-hospital all-cause mortality;—

Secondary

MeasureTime frame
All-time mortality rate;Incidence of complications;—

Countries

China

Contacts

Public ContactJing-bin Huang

The People’s Hospital of Guangxi Zhuang Autonomous Region

hjb010222@163.com+86 139 7875 3833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026